Dr. Stuart Titus Speaks on RSHO-X’s Benefits and Cannabis Industry Updates Around the World
SAN DIEGO, Jan. 23, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC PINK:MJNA), the first-ever publicly traded cannabis company in the United States, was recently featured in an International Business Times article discussing how consumers have used the company’s hemp oil product Real Scientific Hemp Oil-X (RSHO-X) and how Medical Marijuana, Inc. is helping fuel less restrictive medical cannabis programs in Mexico and other countries and expanding markets.
Chief Executive Officer of Medical Marijuana, Inc. Dr. Stuart Titus was interviewed by the widely circulated publication where he discussed RSHO-X and its health benefits to consumers. The article also highlights the difference between cannabidiol (CBD) and tetrahydrocannabinol (THC) and how Medical Marijuana, Inc. received the historic, first-ever permit to import a cannabis product into Mexico for RSHO-X on Feb. 2, 2016.
“We are always excited to work with publications like the International Business Times and help spread the word about Medical Marijuana, Inc.’s goals to help those all over the globe who have been suffering for so long,” said Dr. Titus. “We are glad that countries like Mexico are starting to understand that non-psychoactive CBD has tremendous potential for their people. Our organization looks forward to initiating further research to demonstrate the potential benefits for the medical and scientific community – in directions where our anecdotal evidence points us.”
The article also features discussion on future steps being taken regarding the debate on the schedule 1 status of cannabis-based products. There are continued hopes now that the World Health Organization (WHO) initiated steps to reclassify and re-schedule medical marijuana under international law, which has the potential to open tremendous opportunities around the world including the U.S.
Over the next eighteen months, a special WHO committee has requested pre-reviews for cannabis plant matter, extracts and tinctures, delta-9 THC, CBD, and stereoisomers of THC.
Rescheduling at the international level would have major ramifications for US policy on medical cannabis, as all too often politicians cite the UN Single Convention Treaty on Narcotics as the reason Congress cannot move towards rescheduling cannabis. More info can be found here.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer
P. 888-829- 0070
Investor Relations Contact:
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
Email: [email protected]